Skip to content

Development and Clinical Application of ApoC3 Protein as a Predictive Biomarker for Insulin Resistance in Polycystic Ovary Syndrome

Development and Clinical Application of ApoC3 Protein as a Predictive Biomarker for Insulin Resistance in Polycystic Ovary Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07739953
Enrollment
200
Registered
2026-07-31
Start date
2025-06-01
Completion date
2027-06-30
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCOS (Polycystic Ovary Syndrome)

Brief summary

Polycystic Ovary Syndrome (PCOS) is the most common reproductive endocrine disorder causing infertility and miscarriage in women. The insulin resistance state in PCOS patients (PCOS with insulin resistance, PCOS-IR) not only affects their fertility but is also associated with a range of health issues, including type 2 diabetes mellitus, endometrial cancer, and spontaneous abortion during pregnancy. There is an urgent clinical need to explore sensitive serum biomarkers for the diagnosis of insulin resistance in PCOS. Our preliminary studies have demonstrated that apolipoprotein C-III (ApoC3) exhibits diagnostic efficacy for PCOS-IR and is positively correlated with HOMA-IR, for which we were granted a national invention patent in China in 2016. Building on our research foundation in PCOS insulin resistance, we have developed a rapid detection kit for the ApoC3 protein, enabling early screening of insulin resistance in PCOS. Furthermore, point-of-care testing (POCT) products can achieve rapid quantitative detection of biomarkers. This project has recently been funded by the Guangdong Provincial Department of Science and Technology under the 2024 Guangdong-Hong Kong-Macao Greater Bay Area International Innovation Center Construction Initiative (Guangdong-Hong Kong-Macao Joint Innovation Field).

Interventions

OTHERobservational study

Observational Study

Sponsors

Guangdong Women and Children Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

I. Diagnostic Criteria The 2003 Rotterdam diagnostic criteria for PCOS jointly established by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM): Clinical and/or biochemical signs of hyperandrogenism; Oligo-ovulation or anovulation; Ultrasound findings: ovarian volume ≥ 10 mL, and/or \> 12 follicles with a diameter of 2-9 mm in a single section. A diagnosis of PCOS can be established when at least two of the following three criteria are met: ovarian dysfunction, hyperandrogenism, and polycystic ovarian morphology on ultrasound. II. Inclusion and

Exclusion criteria

1. PCOS with Insulin Resistance (PCOS-IR) Inclusion Criteria: Meets the 2003 Rotterdam diagnostic criteria for PCOS (at least 2 of the following 3 items): ① Oligo-ovulation or anovulation; ② Clinical or biochemical signs of hyperandrogenism; ③ Polycystic ovaries on ultrasound (unilateral or ovarian volume ≥ 10 mL). Insulin resistance (IR), meeting at least 1 of the following 3 criteria: ① HOMA-IR ≥ 2.5; ② Fasting insulin ≥ 15 μIU/mL; ③ Diagnosed impaired glucose tolerance (IGT) or type 2 diabetes mellitus (T2DM).

Design outcomes

Primary

MeasureTime frame
adverse pregnancy outcomes and long-term complications such as type 2 diabetes mellitus1year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026